---
title: "enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289791121.md"
description: "enGene Therapeutics reported a Q3 2026 net loss of $30.2M ($0.43 EPS), widening from the prior year's $25.8M. The company cut its workforce by ~50% to conserve cash for LEGEND study completion and BLA planning. Interim LEGEND results showed a 54% complete response rate, prompting the addition of a surfactant cohort. enGene is advancing CMC and pre-commercial activities toward a potential 2027 launch."
datetime: "2026-06-15T13:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289791121.md)
  - [en](https://longbridge.com/en/news/289791121.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289791121.md)
generator: "portal-rs"
---

# enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary

enGene Therapeutics Inc. reported a net loss of $30.2M for the quarter ended April 30, 2026, compared with a net loss of $25.8M in the year-ago quarter; diluted loss per share was $0.43 versus $0.51 in the prior-year quarter.

**Financial Highlights**

-   Net income: Net loss of $30.2M for the quarter ended Apr 30, 2026, vs. net loss of $25.8M in the year-ago quarter — increased loss of $4.4M YoY.
-   Diluted EPS: Net loss per share (basic & diluted) $0.43 for the quarter ended Apr 30, 2026, vs. $0.51 in the year-ago quarter (down $0.08 YoY).

**Business Highlights**

-   Clinical milestone: Interim results from the LEGEND pivotal cohort showed a 54.0% any-time complete response (CR) rate and Kaplan-Meier–estimated durability at 6–12 months, supporting BLA planning.
-   Program expansion: Company added a surfactant (polidocanol) cohort to the LEGEND study to potentially improve bladder delivery; enrollment has begun for up to ~80 patients.
-   Strategic restructuring: enGene implemented an approximately 50% workforce reduction to conserve cash while retaining resources to complete LEGEND Cohort 1, enroll the surfactant cohort, and pursue BLA activities.
-   Operational readiness: Advanced CMC, clinical operations, and pre-commercial activities, including process validation, to support planned BLA initiation and a potential 2027 launch.

Original SEC Filing: enGene Therapeutics Inc. \[ ENGN \] - 10-Q - Jun. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ENGN.US](https://longbridge.com/en/quote/ENGN.US.md)
- [ENGNW.US](https://longbridge.com/en/quote/ENGNW.US.md)

## Related News & Research

- [Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in Sanfilippo syndrome type B after FDA meetings](https://longbridge.com/en/news/296784399.md)
- [Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA | CAPR Stock News](https://longbridge.com/en/news/296796113.md)
- [Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis](https://longbridge.com/en/news/296776870.md)
- [Vivakor raises 2026 supply and trading outlook to $3.5 billion annualized commercial activity](https://longbridge.com/en/news/296919231.md)
- [Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan | SRRK Stock News](https://longbridge.com/en/news/296622602.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**